TEVA/Celltrion announce that Truxima (rituximab-abbs) is now available in US to treat #RA (w/ MTX) and GPA (Wegeners) at 10% discount (previously approved for CLL, NHL). Other RTX biosimilar, Ruxience (RTX-pvvr) is approved for GPA, not RA. ’https://t.co/TyU21QlcjI
Links:
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) …
https://bit.ly/2zXQdGu
May-04-2020
